Why I’d Buy Tesco PLC, Hold GlaxoSmithKline plc & Dump Diageo PLC

Tesco PLC (LON:TSCO), GlaxoSmithKline plc (LON:GSK) and Diageo PLC (LON:DGE) are under the spotlight.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Three stocks with three different risk profiles: Tesco (LSE: TSCO), GlaxoSmithKline (LSE: GSK) and Diageo (LSE: DGE). Here’s why I’d buy the food retailer, but the other two make me feel a bit nervous.

Before we press on, a caveat: I am working under the assumption that the FTSE 100 will rise between 3% and 6% in 2015. 

Tesco: Looking For “Catalysts”

There’s a lot going on at Tesco, whose full-year results are due on 22 April, when it will have to show that its accounts are in good order. Should you snap up the shares before then? 

Well, it’s highly unlikely that the UK’s largest grocer will disappoint investors in the next couple of quarters, in my view. Management has made good progress in the last few months, with the stock up 47% since its rally started in October. At 244p, Tesco can hardly be defined as a bargain based on the value of its assets, which I estimate to be close to fair value at 237p — but it remains an appealing turnaround story.

In April last year, Tesco traded some 50p higher, and by no means did its future look brighter back then.

Its portfolio of assets is being restructured, with rumours suggesting several divestments will be announced in months to come, including a large stake in Tesco Bank, which should be sold only for a top valuation in my opinion. The grocer recently agreed a real-estate swap with British Land, which was good news as Tesco now owns the freehold of a larger number of its stores.

In the 12 weeks ending 1 February 2015, the grocery market grew at 1.1% — the fastest rate since June 2014, according to Kantar Worldpanel — and Tesco returned to growth for the first time since January 2014, increasing sales by 0.3%. If recent trends are confirmed in the next few quarters, and divestment take place, Tesco could well rise to 300p a share — and could also return to a more generous dividend policy earlier than expected…

Glaxo & Diageo

There are risks associated to Glaxo, which reports first-quarter results in early May. 

Unless management give investors a few good reasons to back the company, shareholders will probably experience more volatility going forward — although one could argue that in less stable market conditions the shares of this pharmaceuticals giant could fare relatively well. I don’t buy into such an optimistic view, and I think Glaxo will likely struggle to deliver rising returns to shareholders, particularly in the second half of 2015. 

Its stock has recorded a stronger performance than that of AstraZeneca in recent times, but it’s much less appealing than Shire over the long term, and it appears to me that it may find it more difficult to outperform the FTSE 100 from this level, unless material news such as the massive spin-out of its HIV drugs business emerges in due course. 

Glaxo is a rather mature business whose shares trade at 20x forward earnings, and although they offer a forward yield above 5%, I’d be more interested to bet on a different recovery story in another defensive sector. So, is Diageo the one right now?

Its third-quarter numbers are due on 16 April; I am afraid, but I am not interested in Diageo at this price, and I think upside is very limited from this level, while downside could be up to 12% this year. 

Diageo recently announced that it had agreed to take full control of United National Breweries in South Africa — and that’s the way forward, but the problem is there aren’t may assets available on the market, so one obvious question is where growth will come from. 

As a mature business with operations worldwide, its valuation is in line with that of Glaxo, based on its earnings multiple, but is 20% higher based on its adjusted operating cash flow multiple, which is a warning sign for a value hunter like me.

Finally, the shares of many of its competitors are more attractively priced. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »